DA
LFCR icon

DCF Advisers’s Lifecore Biomedical LFCR Stock Holding History

DCF Advisers’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,000
Closed -$29K – 101
2023
Q2 		$29K Buy
+3,000
New +$18.3K 0.02% 87

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

DCF Advisers's LFCR Position: Q2 2026 in Review

DCF Advisers held its Lifecore Biomedical (LFCR) position steady in Q2 2026 at 424,500 shares worth $2.23M. The position accounts for 0.39% of the portfolio, ranked #43.

DCF Advisers first reported a position in LFCR in Q2 2023 and has held it in 13 quarters since. The position peaked at $4.01M in Q4 2024. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • DCF Advisers held 424,500 shares of Lifecore Biomedical worth $2.23M as of Q2 2026.
  • DCF Advisers left its Lifecore Biomedical share count unchanged in Q2 2026.
  • Lifecore Biomedical made up 0.39% of DCF Advisers's portfolio in Q2 2026, its #43 holding.
  • DCF Advisers first reported a position in Lifecore Biomedical in Q2 2023 and has held it in 13 quarters since.
  • DCF Advisers's Lifecore Biomedical position peaked at $4.01M in Q4 2024.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.